Flushing and other dermatologic adverse events associated with extended-release niacin therapy

Journal of Clinical Lipidology

Volumn 3, Issue 2, 2009, Pages 101-108

  Guyton, John R ^a   Simmons, Phillip D ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Discovery Laboratories Inc   (United States)

Author keywords

Adverse effects; Dyslipidemia; Extended release niacin; Flushing; Immediate release niacin

Indexed keywords

APOLIPOPROTEIN B; GEMFIBROZIL; LAROPIPRANT; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN D2 RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DATA ANALYSIS; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; DRY SKIN; FLUSHING; HUMAN; HYPOTENSION; PARESTHESIA; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; URTICARIA;

EID: 61949090813     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.02.003     Document Type: Article

References (31)

1. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54 (1955) 558-559
2. Guyton J.R., Blazing M.A., Hagar J., et al. Extended-release niacin versus gemfibrozil for treatment of low levels of high density lipoprotein cholesterol. Arch Intern Med 160 (2000) 1177-1184
3. Guyton J.R. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 5 (2004) 1385-1398
4. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91 (2003) 1432-1436
5. Capuzzi D.M., Morgan J.M., Brusco Jr. O.A., and Intenzo C.M. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2 (2000) 64-71
6. Guyton J.R., and Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 99 suppl. (2007) S22-S31
7. Morrow J.D., Parsons III W.G., and Roberts L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 (1989) 263-274
8. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47 (1998) 1097-1104
9. McKenney J.M. Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 60 (2003) 995-1005
10. Rader J.I., Calvert R.J., and Hathcock J.N. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 92 (1992) 77-81
11. McKenney J.M., Proctor J.D., Harris S., and Chinchili V.M. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271 (1994) 672-677
12. Morgan J.M., Capuzzi D.M., Guyton J.R., et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Therapeut 1 (1996) 195-202
13. Goldberg A., Alagona Jr. P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85 (2000) 1100-1105
14. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan); a long-term study. Am J Cardiol 82 (1998) 74U-81U
15. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 162 (2002) 1568-1576
16. Guyton J.R., Goldberg A.C., Kreisberg R.A., et al. Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82 (1998) 737-743
17. Kos Pharmaceuticals I. Niaspan product information. Physicians Desk Reference (2005), Thomson PDR, Montvale, NJ
18. Hunninghake D.B., McGovern M.E., Koren M., et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 26 (2003) 112-118
19. Insull Jr. W., McGovern M.E., Schrott H., et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 164 (2004) 1121-1127
20. Piepho R.W. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 86 suppl 12A (2000) 35L-40L
21. Knopp R.H., Ginsberg J., Albers J.J., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34 (1985) 642-650
22. Wilkin J.K., Wilkin O., Kapp R., Donachie R., Chernosky M.E., and Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 31 (1982) 478-482
23. Cefali E.A., Simmons P.D., Stanek E.J., and Shamp T.R. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 44 (2006) 633-640
24. Cheng K., Wu T.J., Wu K.K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 103 (2006) 6682-6687
25. Tredaptive (nicotinic acid/laropiprant) authorised in the European Union: new lipid-modifying therapy to treat LDL-C, HDL-C and triglycerides. Available at: http://www.medicalnewstoday.com/articles/115760.php. Accessed August 28, 2008.
26. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
27. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
28. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
29. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res. Opin 22 (2006) 2243-2250
30. National Heart Lung and Blood Institute. Niacin plus statin to prevent vascular events, 2006. Available at: http://www.clinicaltrials.gov/ct/show/NCT00120289. Accessed May 11, 2007.
31. University of Oxford. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE, 2007. Available at: http://www.clinicaltrials.gov/ct/show/NCT00461630. Accessed December 31, 2008.